Evidence Tier: Preclinical — KPV is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) with potent anti-inflammatory properties. Under FDA review for 2026 reclassification.
Overview
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike the full alpha-MSH hormone, KPV retains anti-inflammatory activity without melanogenic (tanning) effects. It has been studied primarily in models of intestinal inflammation and immune disorders.
Mechanism of Action
- NF-kB Inhibition: Directly enters cells and inhibits NF-kB nuclear translocation, reducing inflammatory gene expression
- Cytokine Suppression: Reduces IL-1beta, IL-6, TNF-alpha production in immune cells
- Gut Barrier Enhancement: Improves intestinal epithelial barrier function in colitis models
Regulatory Status
FDA: Scheduled for PCAC evaluation July 23-24, 2026.
References
- Dalmasso G, et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134(1):166-178.
- Kannengiesser K, et al. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflamm Bowel Dis. 2008;14(3):324-331.
Research Disclaimer
This article is compiled from peer-reviewed research and publicly available scientific literature. It is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health-related decisions.